Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Open-label, Study Evaluating Safety and Efficacy of the Loncastuximab in Relapsed/Refractory Marginal Zone Lymphoma

Next Previous
Trial Profile

A Phase 2, Open-label, Study Evaluating Safety and Efficacy of the Loncastuximab in Relapsed/Refractory Marginal Zone Lymphoma

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 23 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 14 May 2025 According to an ADC Therapeutics media release, this trial is being conducted at the Sylvester Comprehensive Cancer Center at University of Miami and City of Hope, data will be presented at ICML
  • 05 Nov 2024 According to an ADC Therapeutics media release, data from this study have been accepted for presentation at the 66th American Society of Hematology (ASH) Annual Meeting, which will be held in San Diego, California from December 7-10, 2024.
  • 05 Nov 2024 Results presented in an ADC Therapeutics Media Release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top